2 assets in Childhood Medulloblastoma

Therapeutic assets addressing Childhood Medulloblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Childhood Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
G 207 Childhood Medulloblastoma	M.D. Anderson Cancer Center	P1	CC (43)